2017
DOI: 10.1016/j.ejmech.2017.06.045
|View full text |Cite
|
Sign up to set email alerts
|

Structural basis for selective inhibition of Cyclooxygenase-1 (COX-1) by diarylisoxazoles mofezolac and 3-(5-chlorofuran-2-yl)-5-methyl-4-phenylisoxazole (P6)

Abstract: The diarylisoxazole molecular scaffold is found in several NSAIDs, especially those with high selectivity for COX-1. Here, we have determined the structural basis for COX-1 binding to two diarylisoxazoles: mofezolac, which is polar and ionizable, and 3-(5-chlorofuran-2-yl)-5-methyl-4-phenylisoxazole (P6) that has very low polarity. X-ray analysis of the crystal structures of COX-1 bound to mofezolac and 3-(5-chlorofuran-2-yl)-5-methyl-4-phenylisoxazole allowed the identification of specific binding determinant… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
57
0
2

Year Published

2019
2019
2022
2022

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 67 publications
(61 citation statements)
references
References 42 publications
1
57
0
2
Order By: Relevance
“…This constriction opens up paving the way for substrates and inhibitors entry to the channel. The catalytic activity of COX-1 is mainly mediated by trapping arachidonic acid (AA) between residues Arg120, Tyr355 and the catalytic Tyr385 [33].…”
Section: Cycloxygenase-1mentioning
confidence: 99%
See 2 more Smart Citations
“…This constriction opens up paving the way for substrates and inhibitors entry to the channel. The catalytic activity of COX-1 is mainly mediated by trapping arachidonic acid (AA) between residues Arg120, Tyr355 and the catalytic Tyr385 [33].…”
Section: Cycloxygenase-1mentioning
confidence: 99%
“…Furthermore, mofezolac is found to participate in hydrogen bonding to Tyr355. It is also surrounded by a rich set of hydrophobic residues in COX1 binding site, which explain its numerous van der Waal interactions [33]. Table 4.…”
Section: Cycloxygenase-1mentioning
confidence: 99%
See 1 more Smart Citation
“…On the other hand, mofezolac 2 ( Fig. 1) was recently developed as selective COX-1 inhibitor with analgesic antiinflammatory potential and low ulcerogenic liability [13]. Mofezolac has also displayed promising anticancer activity in intestinal cancer [14,15].…”
Section: Introductionmentioning
confidence: 99%
“…To further investigate the mechanism of CoxFluor activation by COX‐2, we employed molecular dynamics (MD) and ensemble docking. Previous structures of COX‐1 (PDB 5U6X) and COX‐2 (PDB 5KIR) were selected, ligands were removed and the holoenzyme was simulated in explicit water over a period of 200 ns. Importantly, no global differences were observed for the peptide backbone across a panel of COX‐1 and COX‐2 structures, even in the presence of ligands and substrate (www.rcsb.org, all root‐mean‐standard‐deviation <2.5 Å, Tables S1–2 and Figure S5) .…”
Section: Resultsmentioning
confidence: 99%